Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT03241472
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03238703
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 532
- Registration Number
- NCT03220178
- Locations
- 🇩🇪
University Hospital Mainz, Mainz, Germany
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 37
- Registration Number
- NCT03219476
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
Letrozole Step-up Protocol for Ovulation Induction in Infertile Women With PCOS
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Benha University
- Target Recruit Count
- 90
- Registration Number
- NCT03181919
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT03179904
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 377
- Registration Number
- NCT03161353
- Locations
- 🇫🇷
Hospital Georges Pompidou, Paris, France
🇮🇹Istituto Europeo di Oncologia, Milan, Italy
🇵🇹Hospital Senhora da Oliveira, Guimarães, Portugal
Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 80
- Registration Number
- NCT03135301
- Locations
- 🇪🇬
Assiut Faculty of Medicine, Assiut, Egypt
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03128619
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 133
- Registration Number
- NCT03099174
- Locations
- 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.